Caracterización molecular y fenotípica de bacterias gram negativas resistentes a carbapenemicos por serin carbapenemasas tipo KPC en una institución de cuarto nivel de Bogotá Colombia durante el periodo 2018 a 2021

dc.contributorPérez Franco, Jairo Enrique
dc.contributorMolano-González, Nicolas
dc.creatorChaparro Zuñiga, Smith Yesid
dc.date.accessioned2022-08-05T21:28:24Z
dc.date.accessioned2022-09-22T14:52:21Z
dc.date.available2022-08-05T21:28:24Z
dc.date.available2022-09-22T14:52:21Z
dc.date.created2022-08-05T21:28:24Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/34666
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3442919
dc.description.abstractIntroduction: Resistance to carbapenems by gram-negative bacteria represents a significant loss of last-line drugs for its management. In addition, the current diagnostic methods for the identification of these mechanisms are not widely used in hospital entities. The knowledge of the local epidemiology allows to guide anticipated treatments, reducing associated morbidity and mortality. Objectives: To describe the distribution of the KPC gene in gram-negative bacteria resistant to carbapenems and its relationship with phenotypic identification and differentiation tests. Methods: An observational, descriptive, cross-sectional study was carried out. The study population consisted of gram-negative bacteria, resistant to carbapenems, with identification of the KPC gene, by molecular panel, in adult patients who were hospitalized at the Fundación cardioinfantil during the years 2018 to 2021. Results: 135 sepsis molecular panels were evaluated, of which 41 detected the KPC gene. K. pneumoniae was the germ mainly found globally (60.9%) and in each of the services studied (ICU 68%, hospitalization 45.5% and emergency room 60%). The phenotypic tests, specifically the Hodge and boronic acid tests, had a 93.8% concordance with the molecular test. Conclusions: K. pneumoniae continues to be the main germ resistant to carbapenems due to KPC-type serine carbapenemases.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherEspecialización en Infectología
dc.publisherEscuela de Medicina y Ciencias de la Salud
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-NoComercial-CompartirIgual 2.5 Colombia
dc.sourceBush K. Past and present perspectives on β-lactamases. Vol. 62, Antimicrobial Agents and Chemotherapy. 2018. p. 1–20.
dc.sourceQueenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev. 2007;20(3):440–58
dc.sourceOvalle MV, Saavedra SY, González MN, Hidalgo AM, Duarte C, Beltrán M. Resultados de vigilancia nacional de la resistencia antimicrobiana. Biomedica. 2017;37:473–85.
dc.sourceTeo J, Cai Y, Lim T-P, Tan T, Kwa A. Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms. 2016;4(1):13
dc.sourcesalme, Timmusk. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. Front Plant Sci. 2012;0954162(478):1–4.
dc.sourceVasoo S, Barreto JN, Tosh PK. Emerging Issues in Gram-Negative Bacterial Resistance: An Update for the Practicing Clinician. Mayo Clin Proc [Internet]. 2015;90(3):395–403. Available from: http://dx.doi.org/10.1016/j.mayocp.2014.12.002
dc.sourceFalcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):1–12.
dc.sourceVillegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;23(4):388–98.
dc.sourceVasiliki Tsolaki, a Konstantinos Mantzarlis, a Athanasios Mpakalis, a Ergina Malli, b Fotios Tsimpoukas, c Athanasia Tsirogianni, c Constantinos Papagiannitsis, b Paris 36 Zygoulis, a Maria-Eirini Papadonta, a Efthimia Petinaki, b Demosthenes Makris a EZ. crossm Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically. 2020;64(3):1–11.
dc.sourceYee R, Dien Bard J, Simner PJ. The Genotype to Phenotype Dilemma: How Should Laboratories Approach Discordant Susceptibility Results? J Clin Microbiol. 2021;(January)
dc.sourceLogan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28–36.
dc.sourceZhu Y, Huang WE, Yang Q. Clinical Perspective of Antimicrobial Resistance in Bacteria. Infect Drug Resist. 2022;15(March):735–46.
dc.sourceKelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents [Internet]. 2017;50(2):127– 34. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2017.03.012
dc.sourceBrink AJ. Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr Opin Infect Dis. 2019;609–16
dc.sourceLynch JP, Zhanel GG, Clark NM. Infections Due to Acinetobacter baumannii in the ICU: Treatment Options. Semin Respir Crit Care Med. 2017;38(3):311–25
dc.sourceEichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. Antibiotics. 2019;8(2)
dc.sourceINS. Informe De Resultados De La Vigilancia Por Laboratorio De Resistencia Antimicrobiana En Infecciones Asociadas a La Atención En Salud (Iaas) 2018 Dirección. Epidemiol las Infecc Asoc a la atención en salud. 2019;29–44.
dc.sourceVillegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class a carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880–2.
dc.sourceVillegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother. 2007;51(4):1553–5.
dc.sourceBoyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-lactamases: Structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):1–20.
dc.sourceRojo V, Vázquez P, Reyes S, Fuertes LP, Cervero M. Risk factors and clinical evolution of carbapenemase-producing klebsiella pneumoniae infections in a university hospital in Spain. Case-control study. Rev Esp Quimioter. 2018;31(5):427–34.
dc.sourceFriedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant enterobacteriaceae: A strategic roadmap for infection control. Infect Control Hosp Epidemiol. 2017;38(5):580–94.
dc.sourceRuppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram- negative bacilli. Ann Intensive Care. 2015;5(1).
dc.sourceSze DTT, Lau CCY, Chan TM, Ma ESK, Tang BSF. Comparison of novel rapid diagnostic of blood culture identification and antimicrobial susceptibility testing by Accelerate Pheno system and BioFire FilmArray Blood Culture Identification and BioFire FilmArray Blood Culture Identification 2 panels. BMC Microbiol [Internet]. 2021;21(1):1–15. Available from: https://doi.org/10.1186/s12866-021-02403-y
dc.sourceSalimnia H, Fairfax MR, Lephart PR, Schreckenberger P, DesJarlais SM, Johnson JK, et al. Evaluation of the FilmArray Blood Culture Identification Panel: Results of a Multicenter Controlled Trial. J Clin Microbiol. 2016;54(3):687–98.
dc.sourceSchneider JG, Wood JB, Schmitt BH, Emery CL, Davis TE, Smith NW, et al. Susceptibility Provision Enhances Effective De-escalation (SPEED): Utilizing rapid phenotypic susceptibility testing in Gram-negative bloodstream infections and its potential clinical impact. J Antimicrob Chemother. 2019;74:I16–23.
dc.sourceBassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis. 2020;7:1–12.
dc.sourceCosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(SUPPL. 2):82–9.
dc.sourceAssociation WM. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013 Sep 22;310(20):2191–4.
dc.sourceMinisterio de salud. RESOLUCION NUMERO 8430 DE 1993. Minsterio de salud. 1993;1–19.
dc.sourceSotgiu G, Are BM, Pesapane L, Palmieri A, Muresu N, Cossu A, et al. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect [Internet]. 2018;99(4):413–8. Available from: https://doi.org/10.1016/j.jhin.2018.03.033
dc.sourceGupta N, Limbago BM, Patel JB, Kallen AJ, Sotgiu G, Are BM, et al. Carbapenem- resistant enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis [Internet]. 2018;53(4):413–8. Available from: https://doi.org/10.1016/j.jhin.2018.03.033
dc.sourceKunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther [Internet]. 2022;11(2):661–82. Available from: https://doi.org/10.1007/s40121-022- 00591-2
dc.sourceEsparza G. Bacterias Gram negativas resistentes a carbapenemicos en Colombia: un desafío continuo al sistema de salud. Infectio. 2020;24(2):55–6.
dc.sourceMarco F. Métodos moleculares para el diagnóstico de septicemia. Enferm Infecc Microbiol Clin. 2017;35(9):586–92.
dc.sourceSalomão MC, Guimarães T, Duailibi DF, Perondi MBM, Letaif LSH, Montal AC, et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect.
dc.sourceRemolina S, Escobar C. DESCRIPCIÓN DE TIPOS DE CARBAPENEMASAS EXPRESADAS EN Klebsiella sp. y Pseudomonas aeruginosa EN HOSPITALES DE TERCER NIVEL DE LA CIUDAD DE BOGOTÁ, ESTUDIO DESCRIPTIVO. Univ Nac Colomb. 2018;
dc.sourceTamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018;56(11):1–13.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectBacterias gram negativas
dc.subjectGen KPC
dc.subjectSerin carbapenemasa
dc.subjectAcido boronico
dc.subjectTest de hodge
dc.subjectEDTA
dc.titleCaracterización molecular y fenotípica de bacterias gram negativas resistentes a carbapenemicos por serin carbapenemasas tipo KPC en una institución de cuarto nivel de Bogotá Colombia durante el periodo 2018 a 2021
dc.typemasterThesis


Este ítem pertenece a la siguiente institución